Dermapharm Holding SE (DE:DMP)
XETRA:DMP
Want to see DE:DMP full AI Analyst Report?
Top Page
Dermapharm Holding SE
(XETRA:DMP)
Select Model
Select Model
Rating:69Neutral
Price Target:
€47.00
▲(1.73% Upside)
Action:DowngradedDate:04/10/26
The score is driven primarily by solid but not top-tier financial fundamentals: good revenue momentum and supportive cash generation are offset by margin compression and elevated leverage. Technicals add support as the stock is in an uptrend with positive MACD and neutral RSI. Valuation is reasonable with a mid-teens P/E and a modest dividend yield.
Positive Factors
Multi-year revenue expansion
Sustained top-line expansion through 2025 indicates durable demand for the product portfolio and effective lifecycle management. Consistent revenue traction supports reinvestment in R&D, product launches and commercial reach, underpinning longer-term earnings capacity despite cyclical pressures.
Negative Factors
Meaningful margin compression
Sustained margin erosion reduces operating leverage and leaves earnings exposed to cost inflation, pricing and reimbursement pressures. If margins remain compressed, cash available for reinvestment and deleveraging falls, weakening the firm's ability to finance growth without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue expansion
Sustained top-line expansion through 2025 indicates durable demand for the product portfolio and effective lifecycle management. Consistent revenue traction supports reinvestment in R&D, product launches and commercial reach, underpinning longer-term earnings capacity despite cyclical pressures.
Read all positive factors
Dermapharm Holding SE (DMP) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€2.30B
Dividend Yield2.34%
Average Volume (3M)18.50K
Price to Earnings (P/E)14.4
Beta (1Y)0.56
Revenue Growth-1.34%
EPS Growth16.37%
CountryDE
Employees3,610
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.69
Shares Outstanding49,540,810
10 Day Avg. Volume17,993
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.05
Price to Sales (P/S)1.82
P/FCF Ratio15.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€34.00Price Target Upside-26.41% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)2.52
Revenue Forecast (FY)€1.23B
Dermapharm Holding SE Business Overview & Revenue Model
Company Description
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel I...
How the Company Makes Money
Dermapharm makes money primarily by selling pharmaceutical and health products and by providing manufacturing-related services. Its key revenue streams typically include: (1) Prescription pharmaceuticals: revenue from selling branded generics and ...
Dermapharm Holding SE Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
56
Neutral
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.16B | 1.18B | 1.14B | 1.02B | 942.91M |
| Gross Profit | 391.71M | 767.07M | 719.16M | 660.83M | 620.69M |
| EBITDA | 314.31M | 320.91M | 265.55M | 329.81M | 358.10M |
| Net Income | 132.41M | 113.79M | 62.37M | 134.24M | 209.58M |
Balance Sheet | |||||
| Total Assets | 2.20B | 2.08B | 2.16B | 1.41B | 1.41B |
| Cash, Cash Equivalents and Short-Term Investments | 203.41M | 121.71M | 159.54M | 161.36M | 172.06M |
| Total Debt | 1.05B | 979.61M | 1.08B | 516.45M | 580.30M |
| Total Liabilities | 1.50B | 1.47B | 1.62B | 880.34M | 907.13M |
| Stockholders Equity | 694.38M | 604.42M | 539.21M | 531.59M | 497.32M |
Cash Flow | |||||
| Free Cash Flow | 139.39M | 163.14M | 177.88M | 249.52M | 189.16M |
| Operating Cash Flow | 181.51M | 201.38M | 219.42M | 288.53M | 250.37M |
| Investing Cash Flow | -110.03M | -29.61M | -415.43M | -99.01M | -129.35M |
| Financing Cash Flow | 13.32M | -209.17M | 204.54M | -199.77M | -80.98M |
Dermapharm Holding SE Technical Analysis
Positive
46.20
Price Trends
40.72
Positive
38.95
Positive
36.19
Positive
Market Momentum
1.42
Negative
62.06
Neutral
74.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DMP, the sentiment is Positive. The current price of 46.2 is above the 20-day moving average (MA) of 43.72, above the 50-day MA of 40.72, and above the 200-day MA of 36.19, indicating a bullish trend. The MACD of 1.42 indicates Negative momentum. The RSI at 62.06 is Neutral, neither overbought nor oversold. The STOCH value of 74.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:DMP.
Dermapharm Holding SE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €2.30B | 14.36 | 20.45% | 2.34% | -1.34% | 16.37% | |
58 Neutral | €47.85B | 20.44 | 9.02% | 1.82% | -0.26% | -6.09% | |
56 Neutral | €349.43M | 23.60 | 2.97% | ― | 10.39% | 19.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €319.88M | -6.99 | -16.02% | ― | -36.17% | 48.61% |
* Healthcare Sector Average
DE:DMP
Dermapharm Holding SE
46.35
7.73
20.01%
DE:B8FK
Biofrontera
2.57
0.29
12.72%
DE:MRK
Merck KGaA
110.05
-13.23
-10.73%
DE:ILM1
Medios AG
13.70
1.46
11.93%
DE:PHH2
PAUL HARTMANN AG
204.00
-37.25
-15.44%
DE:FYB
Formycon AG
18.10
-5.15
-22.15%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.